article information

Hepatitis Monthly: Vol.14, issue 11; 25540
published online: November 22, 2014
article type: Editorial
received: November 21, 2014
accepted: November 22, 2014
DOI: 10.5812/hepatmon.25540
Crossmark

Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?

authors:

avatar Mohamad Amin Pourhoseingholi 1 , avatar Sara Ashtari 1 , avatar Seyed Moayed Alavian ORCID 2 , *

Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Middle East Liver Diseases Center (MELD), Tehran, IR Iran

how to cite: Pourhoseingholi M A, Ashtari S, Alavian S M. Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?. Hepat Mon.14(11):25540. doi: 10.5812/hepatmon.25540.

Abstract

This article does not have abstract.

Full Text

Full text is available in PDF

© 2014, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.